Single institutions reported response rates of 50–90% in refractory B cell malignancies to anti-CD19 chimeric antigen receptor (CAR) T cells, and 80% in advanced myeloma to T cell Receptor (TCR) T cells against cancer antigens [1–5]. The gene discussed is CD19; the disease is cancer.